Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion Confirms EU Bevacizumab Filing

CT-P16 Biosimilar Rival To Avastin Has Been Submitted To The EMA

Executive Summary

Celltrion has confirmed that it has now filed its CT-P16 proposed bevacizumab rival to Avastin with the European Medicines Agency, having previously submitted it to regulators in both Korea and the US.

You may also be interested in...



BioMarin’s Roctavian & Argenx’s Efgartigimod Among Eight Hopefuls Awaiting EU Verdict

Will BioMarin be second time lucky with its hemophilia gene therapy Roctavian in the EU? The European Medicines Agency could soon decide whether the product should be approved.

Samsung Bioepis Toasts First Bevacizumab Biosimilar In Korea

Samsung Bioepis has expanded its portfolio of biosimilar products in its domestic South Korea, with the launch of bevacizumab via partner Boryung Pharmaceutical.

Grindeks Sets Out Plans For International Expansion

Latvia’s Grindeks has set out plans to expand internationally, including by opening new subsidiaries in the US, Switzerland and EU, following a year of growth for the company.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel